Investigational drug · Phase 3
obudanersen
Also called: ION582
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Angelman Syndrome.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
2
Any phase or sponsor naming "obudanersen"
First trial start
2021
Dec 22, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "obudanersen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Angelman Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "obudanersen" as an intervention, largest first.
- REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman SyndromePivotal-lookingActive, not recruiting
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT06914609 · 156 participants · Start Jun 10, 2025 · Primary completion Aug 2027
Drug: obudanersen; Placebo · For: Angelman Syndrome
Sites: Los Angeles, California; San Diego, California; Aurora, Colorado · 39 sites in all
- CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)Pivotal-lookingRecruiting
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT07782827 · 30 participants (planned) · Start Sep 30, 2026 · Primary completion May 2028
Drug: obudanersen · For: Angelman Syndrome
Sites: Carrboro, North Carolina
Newest research
PubMed records naming it or its code names, newest first.
Also in development for Angelman Syndrome
- rugonersenPhase 31 trial
OHB Pediatrics Ltd. · Angelman Syndrome
- GTX-102Phase 21 trial
Ultragenyx Pharmaceutical Inc · Angelman Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Ionis Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.